Abbott

157 articles with Abbott

• Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes

  10/14/2019

  Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes

• Late-Breaking Data Shows Abbott's MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life

  9/29/2019

  New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone

• U.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors in Diagnosing Heart Attacks Faster and More Accurately

  9/25/2019

  Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test has received clearance from the U.S. Food and Drug Administration (FDA).

• Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children

  9/17/2019

  Abbott (NYSE: ABT) today announced approvals in Europe for two of its life-saving pediatric devices.

• Abbott Named the Industry Leader in Sustainability for the Seventh Consecutive Year on the Dow Jones Sustainability Index (DJSI)

  9/16/2019

  Abbott (NYSE: ABT) has been named the Global Industry Leader in sustainability for the seventh consecutive year by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability.

• Abbott and Sanofi Partner to Integrate Glucose Sensing and Insulin Delivery Technologies to Help Change the Way Diabetes is Managed

  9/16/2019

  Abbott (NYSE: ABT) and Sanofi are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.

• Abbott's Revolutionary FreeStyle® Libre System Now Reimbursed in the Two Largest Provinces in Canada

  9/13/2019

  Abbott (NYSE: ABT), the global leader in sensor-based glucose monitoring, announced today that it has received public reimbursement in Ontario and Quebec for its FreeStyle® Libre system, becoming the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

• Abbott Declares 383rd Consecutive Quarterly Dividend

  9/12/2019

  The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.

• Abbott Announces New Data That Shows Artificial Intelligence Technology Can Help Doctors Better Determine Which Patients are Having a Heart Attack

  9/10/2019

  Abbott announced that new research, published in the journal Circulation, found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not, so that they can receive faster treatments or be safely discharged.

• Abbott Launches World's First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves

  9/5/2019

  TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation

• Together, We Can Increase the Number of Women in STEM: Here is a Tool to Help Companies Get Started

  8/26/2019

  We know the facts: Girls are less likely to be encouraged to study science, technology, engineering and math.

• Abbott Reports Second-Quarter 2019 Results

  7/17/2019

  Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019.

• Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform

  7/15/2019

  Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation

• Nutrition Is the Missing Ingredient in Home Health Today, New Study Shows

  6/24/2019

  Real-world data from Advocate Health Care and Abbott shows prioritizing nutrition care for home health patients helped keep them out of the hospital

• Abbott Hosts Conference Call for Second-Quarter Earnings on July 17, 2019

  6/19/2019

  Abbott will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.

• Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

  6/17/2019

  Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation

• Abbott Declares Consecutive Quarterly Dividend

  6/14/2019

  The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.

• New Survey Shows Millennials Can Help Avoid Blood Shortages

  6/13/2019

  A new survey from Abbott finds that millennials may be the key to a growing public health problem: a shortage in donated blood.

• New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes

  6/8/2019

  Abbott announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring technology, significantly reduced hemoglobin A1c levels for people living with Type 2 diabetes on intensive insulin therapy.

• New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results

  5/16/2019

  Abbott's ZonePerfect Keto shakes and powders are formulated with a science-based macronutrient ("macros") ratio of 75% fat, 20% protein and 5% carbohydrates to support ketosis and burn body fat